Home/Filings/4/0001562180-24-001984
4//SEC Filing

Giladi Moshe 4

Accession 0001562180-24-001984

CIK 0001645113other

Filed

Feb 28, 7:00 PM ET

Accepted

Feb 29, 4:33 PM ET

Size

12.4 KB

Accession

0001562180-24-001984

Insider Transaction Report

Form 4
Period: 2024-02-27
Giladi Moshe
Chief Science Officer
Transactions
  • Award

    Ordinary Shares

    2024-02-27$16.30/sh+51,124$833,32169,771 total
  • Award

    Stock Options (Right to buy)

    2024-02-27$16.30/sh+78,174$1,274,23678,174 total
    Exercise: $16.30From: 2025-02-27Exp: 2034-02-26Ordinary Shares (78,174 underlying)
Footnotes (2)
  • [F1]Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
  • [F2]Options to buy 78,174 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

Issuer

NovoCure Ltd

CIK 0001645113

Entity typeother

Related Parties

1
  • filerCIK 0002001639

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Feb 29, 4:33 PM ET
Size
12.4 KB